Data extracted from a primary prevention trial showed that aspirin significantly increases overall gastrointestinal (GI) bleeding risk in the elderly. The trial was conducted throughout 2010–2017 (n=19 114) in community-dwelling persons aged ≥70 years with low-dose enteric-coated aspirin or placebo. Over a median follow-up of 4.7 years (88 389 person years), there were 137 upper GI bleeds (89 in aspirin vs 48 in placebo arm, HR 1.87) and 127 lower GI bleeds (73 in aspirin vs 54 in placebo arm, HR 1.36) reflecting a 60% increase in bleeding overall. Multivariable analyses indicated age, smoking, hypertension, chronic kidney disease and obesity increased bleeding risk. The absolute 5-year risk of bleeding was 0.25% for a 70 years old not on aspirin and up to 5.03% for an 80 years old taking aspirin with additional risk factors. The study provides population-based data on GI bleeding in older populations, and suggests a more nuanced approach to prescribing aspirin, taking into account the risk of adverse effects such as bleeding versus the benefit of preventing cardiovascular disease. Source: https://gut.bmj.com/
A secondary MRI analysis of the US POINTER randomized clinical trial found that a structured…
Dementia risk factors vary substantially across countries, but they frequently cluster together in similar patterns…
A systematic review and network meta-analysis of 262 randomized trials involving 99,791 participants found that…
Approximately 21% of patients with phenotypically mild hypertrophic cardiomyopathy (HCM) experienced major adverse cardiovascular events…
A Danish randomized crossover trial found that a single session of high-intensity interval exercise (HIIE)…
Baseline use of proton pump inhibitors (PPIs) and, to a lesser extent, antibiotics was associated…
This website uses cookies.